Description
The study demonstrates clear CNS efficacy in vivo but doesn’t address the pharmacokinetic mechanism by which this small molecule HGF modulator reaches brain tissue. This gap is critical for understanding dosing strategies and therapeutic window optimization in clinical trials.
Gap type: unexplained_observation Source paper: Fosgonimeton attenuates amyloid-beta toxicity in preclinical models of Alzheimer’s disease. (2024, Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, PMID:38599894)
Resolution criteria
Resolution requires: (1) BBB permeability assay (in situ brain perfusion or paracellular flux) measuring fosgonimeton vs control compounds across human iPSC-derived BBB model, showing ≥10-fold penetration advantage; (2) efflux transporter (P-gp, BCRP) interaction study confirming low substrate propensity; (3) target engagement biomarker (p-AKT, p-GSK3β) in brain tissue after IV dosing at therapeutic concentrations. Cell monolayer assays alone are insufficient for in vivo prediction.
Evidence summary
{“resolution_pipeline”: “scidex.atlas.gap_closure_pipeline”, “task_id”: “f4f7b129-0f43-4c84-abd8-20d4e701842d”, “evaluated_at”: “2026-04-28T19:10:16.351630+00:00”, “resolution_summary”: “Resolved by hypothesis h-7e9718dbda: pH-Sensitive Bispecific Antibody Targeting Transferrin Receptor for CNS Delivery. Supporting evidence includes debate sess_SDA-2026-04-07-gap-pubmed-20260406-041445-ce0abc1e_task_73907230.”, “match_counts”: {“hypothesis_matches”: 2, “debate_matches”: 5, “paper_matches”: 0}, “hypothesis_matches”: [{“id”: “h-7e9718dbda”, “title”: “pH-Sensitive Bispecific Antibody Targeting Transferrin Receptor for CNS Delivery”, “score”: 0.237, “reason”: “24 token overlaps; entity overlap: cns”, “analysis_id”: “SDA-2026-04-02-gap-bbb-antibody-transport”, “target_gene”: “TFRC (TfR1); endosomal acidification pathway”, “target_pathway”: null, “disease”: “neurodegeneration”, “composite_score”: 0.8, “confidence_score”: 0.33, “status”: “proposed”, “pubmed_evidence_ids”: [“15850657”, “25144875”, “28642236”, “29358320”, “29893515”]}, {“id”: “h-013cc31a80”, “title”: “Focused Ultrasound with Microbubble Contrast Agents for Antibody CNS Delivery”, “score”: 0.23, “reason”: “22 token overlaps; entity overlap: cns”, “analysis_id”: “SDA-2026-04-02-gap-bbb-antibody-transport”, “target_gene”: “CLDN5/ZO-1 tight junction complex; KDR/VEGFR2”, “target_pathway”: null, “disease”: “neurodegeneration”, “composite_score”: 0.7364, “confidence_score”: 0.81, “status”: “proposed”, “pubmed_evidence_ids”: [“12417458”, “27282890”, “31270484”, “34140622”, “36982361”]}], “debate_matches”: [{“id”: “sess_SDA-2026-04-07-gap-pubmed-20260406-041445-ce0abc1e_task_73907230”, “title”: “The abstract states that AQP4 ‘is part of the pathogenesis’ of CNS disorders and shows ‘notable variability’ in these conditions, but the precise causal mechanisms linking AQP4 alterations to disease development remain unexplained. Understanding these mechanisms is critical for developing AQP4-targeted therapeutics.\n\nGap type: unexplained_observation\nSource paper: Aquaporin-4 in glymphatic system, and its implication for central nervous system disorders. (2023, Neurobiol Dis, PMID:36796590)”, “score”: 0.443, “reason”: “8 token overlaps; entity overlap: cns, pmid”, “analysis_id”: “SDA-2026-04-07-gap-pubmed-20260406-041445-ce0abc1e”, “quality_score”: 0.757, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-15-gap-pubmed-20260411-093843-0a9326c2_20260416-032731”, “title”: “The abstract identifies BACE1 as an attractive drug target but doesn’t address its normal physiological roles. Understanding these functions is critical to predict potential adverse effects of BACE1 inhibitors in therapeutic development.\n\nGap type: open_question\nSource paper: BACE1: the beta-secretase enzyme in Alzheimer’s disease. (2004, Journal of molecular neuroscience : MN, PMID:15126696)”, “score”: 0.417, “reason”: “10 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-15-gap-pubmed-20260411-093843-0a9326c2”, “quality_score”: 0.76, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-15-gap-pubmed-20260411-090658-7651c1d2_20260416-033018”, “title”: “The abstract shows p53 is a central regulator of C9orf72-mediated neurodegeneration but doesn’t explain how poly(PR) specifically activates p53. Understanding this upstream trigger mechanism is critical for developing targeted therapeutic interventions.\n\nGap type: unexplained_observation\nSource paper: p53 is a central regulator driving neurodegeneration caused by C9orf72 poly(PR). (None, None, PMID:33482083)”, “score”: 0.412, “reason”: “10 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-15-gap-pubmed-20260411-090658-7651c1d2”, “quality_score”: 0.61, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-08-gap-pubmed-20260406-062202-5c32c50a_task_9aae8fc5”, “title”: “AD patients with TDP-43 pathology show worse cognitive impairment, but how TDP-43 mechanistically contributes to this severity is unknown. Understanding this could identify TDP-43 as a therapeutic target for cognitive preservation in AD.\n\nGap type: unexplained_observation\nSource paper: TDP-43 Pathology in Alzheimer’s Disease. (2021, Mol Neurodegener, PMID:34930382)”, “score”: 0.41, “reason”: “9 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-08-gap-pubmed-20260406-062202-5c32c50a”, “quality_score”: 0.734, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-14-gap-pubmed-20260410-183021-c13d9f04”, “title”: “The abstract describes astrocyte phenotypic heterogeneity (A1/A2) but doesn’t explain the mechanistic switches governing this critical fate decision. Understanding these mechanisms is essential for therapeutic targeting of beneficial vs harmful astrocyte responses.\n\nGap type: unexplained_observation\nSource paper: Contribution of astrocytes to neuropathology of neurodegenerative diseases. (2021, Brain research, PMID:33516810)”, “score”: 0.407, “reason”: “10 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-14-gap-pubmed-20260410-183021-c13d9f04”, “quality_score”: 0.66, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}], “paper_matches”: []}